Local tumor control and morbidity after one to three fractions of stereotactic external beam irradiation for uveal melanoma

2000 ◽  
Vol 55 (2) ◽  
pp. 135-144 ◽  
Author(s):  
Martin Zehetmayer ◽  
Klaus Kitz ◽  
Rupert Menapace ◽  
Adolf Ertl ◽  
Harald Heinzl ◽  
...  
Author(s):  
John M Varlotto ◽  
John C Flickinger ◽  
Douglas Kondziolka ◽  
L.D Lunsford ◽  
Melvin Deutsch

2001 ◽  
Vol 165 (3) ◽  
pp. 867-870 ◽  
Author(s):  
JONATHAN I. IZAWA ◽  
PAUL PERROTTE ◽  
GRAHAM F. GREENE ◽  
SHELLIE SCOTT ◽  
LAWRENCE LEVY ◽  
...  

Cancers ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 3086
Author(s):  
Miltiadis Fiorentzis ◽  
Ekaterina A. Sokolenko ◽  
Nikolaos E. Bechrakis ◽  
Saskia Ting ◽  
Kurt W. Schmid ◽  
...  

Electrochemotherapy (ECT) is emerging as a complementary treatment modality for local tumor control in various cancer entities. Irradiation is an established therapeutic option for oncologic patients, which is commonly combined with chemotherapy due to its insufficient targeting ability. The efficiency of radiotherapy for tumors can be enhanced with different radiosensitizers. ECT can potentiate the radiosensitizing effect of chemotherapeutic agents such as bleomycin. The present study aims to evaluate the radiosensitizing effect of concomitant ECT with bleomycin on 3D tumor spheroids with primary and radioresistant uveal melanoma cell lines (UPMD2, UPMM3, UM92.1, Mel270) and irradiation. The changes in the spheroid growth and the cell viability as well the cytotoxic long-term effect of the combination treatment were evaluated with various combinations of electroporation settings and bleomycin concentrations as well as radiotherapy doses. A broad range of radiosensitivity was documented among the spheroids from different uveal melanoma cell lines. The primary cell lines showed a higher radiosensitivity and required lower irradiation and bleomycin doses. The maximal tumor control with a reduction of cell survival <10% was achieved with a 5 Gy irradiation only in the primary uveal melanoma cell lines and in combination with all tested ECT settings, whereas the same result could be obtained in UM92.1 spheroids only after ECT with 20 Gy irradiation. Based on the spheroid growth and the measurement of the cross-sectional area, the Mel270 spheroids, originating from a previously irradiated recurrent uveal melanoma, required higher doses of bleomycin and ECT settings after irradiation with 5 Gy in order to achieve a significant growth reduction. No significant difference could be demonstrated for the reduction of cell viability in the combination therapy with 20 Gy and 1000 V/cm between 1 and 2.5 µg/mL bleomycin even in Mel270 spheroids, underlying the importance of a drug delivery system to potentiate the radiosensitizing effect of agents in lower doses. ECT should be further assessed for its applicability in clinical settings as a therapeutic radiosensitizing option for radioresistant tumors and a sufficient local tumor control with lower chemotherapy and irradiation doses.


1990 ◽  
Vol 19 (1) ◽  
pp. 117-122 ◽  
Author(s):  
John C. Flickinger ◽  
L.Dade Lunsford ◽  
Jeffrey Singer ◽  
Elmer R. Cano ◽  
Melvin Deutsch

2019 ◽  
Vol 60 (4) ◽  
pp. 490-500 ◽  
Author(s):  
Shohei Okazaki ◽  
Kazutoshi Murata ◽  
Shin-ei Noda ◽  
Yu Kumazaki ◽  
Ryuta Hirai ◽  
...  

AbstractDefinitive radiotherapy for cervical cancer consists of external-beam radiotherapy (EBRT) and brachytherapy. In EBRT, a central shield (CS) reduces the dose to the rectum and bladder. The combination of whole-pelvic (WP)- and CS-EBRT and brachytherapy is the standard radiotherapy protocol in Japan. Despite clinical studies, including multi-institutional clinical trials, showing that the Japanese treatment protocol yields favorable treatment outcomes with low rates of late radiation toxicities, dose–volume parameters for the Japanese treatment protocol remain to be established. We conducted a retrospective dose–volume analysis of 103 patients with uterine cervical cancer treated with the Japanese protocol using computed tomography–based adaptive brachytherapy. The 2-year overall survival and 2-year local control rates according to FIGO stage were 100% and 100% for Stage I, 92% and 94% for Stage II, and 85% and 87% for Stage III–IV, respectively. Late adverse effects in the rectum and bladder were acceptable. Receiver operating characteristic analysis discriminated recurrence within the high-risk clinical target volume (HR-CTV) (n = 5) from no local recurrence (n = 96), with the optimal response obtained at a dose of 36.0 GyEQD2 for HR-CTV D90 and 28.0 GyEQD2 for HR-CTV D98. These values were used as cut-offs in Fisher exact tests to show that high HR-CTV D90 and HR-CTV D98 doses for brachytherapy sessions were significantly associated with tumor control within the HR-CTV. These data suggest a contribution of brachytherapy to local tumor control in WP- and CS-EBRT and brachytherapy combination treatment, warranting validation in multi-institutional prospective studies.


Sign in / Sign up

Export Citation Format

Share Document